옵션 체인은 다양한 행사가격과 만기일에 대한 Centene의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Centene에 대한 시장 심리를 평가합니다..

Centene (NYSE:CNC) 주식, 옵션 체인

Centene

Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.

Washington,Dc,,United,States,,March,21,2025:president,Donald,Trump,Stops

Government

Large Cap

News

Regulations

Health Care

Politics

Movers

Tech

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

ENPH

FSLR

PLTR

도널드 트럼프 대통령의 대규모 입법안은 예상대로 분열을 일으키고 있다. 공화당은 &#34;하나의 크고 아름다운 법안&#34;(One, Big Beautiful Bill)이라고 홍보하고 있지만 민주당은 &#34;하나의 크고 아름다운 배신&#34;이라고 부르고 있다. 이 법안의 주요 내용을 몇 가지 살펴보자. 

트럼프의 대규모 입법안 &#39;크고 아름다운 법안&#39;에 영향 받을 종목은?

Wuhan.china-may,2021:,Nio,Brand,Logo,With,Electric,Car,In,Store.

Short Sellers

Trading Ideas

ASML

ERIE

KLAC

LRCX

Citigourp Global Markets 2% Protected Notes Linked To The Djia

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 니오(NYSE:NIO)의 주식이 지난주 16.35% 하락했다. 이는 미국에 상장된 중국 주식들이 중국의 9월 수출이 예상치를 밑돌면서 하락한 후 발생한 일이다. 중국 경기 부양책에 대한 불확실성도 최근 주식에 악영향을 미쳤다.

니오, ASML 및 CVS 헬스는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 14일-18일)

Centene Corp

Canna Corp

CHINA NUCLEAR ENERGY TECH by CHINA NUCLEAR ENERGY TECHNOLOGY CORP LTD.

Coincheck Group NV

CANCER CAPITAL CORP by Cancer Capital Corp.

Cancer Capital Corp

CONNECTED MEDIA TECHS INC by Connected Media Technologies, Inc.

Connected Media Technologies Inc

CHUN CAN CAPITAL GROUP by Chun Can Capital Group

Chun Can Capital Group

Core Nickel Corp

CONDUIT CAPITAL LTD ORD by Conduit Capital Ltd.

Range Cancer Therapeutics ETF

CHINA CASTSON 81 FINCE by CHINA CASTSON 81 FINANCE CO.

China Teletech Holding Inc

Cluster Group Holdings Ltd Co

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 20 years by 2.34% on an annualized basis producing an average annual return of 10.65%. Currently, Centene has a market capitalization of $30.97 billion. 
Buying $1000 In CNC: If an investor had bought $1000 of CNC stock 20 years ago, it would be worth $7,575.55 today based on a price of $62.23 for CNC at the time of writing.
<h3>Centene's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747753218_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

President Donald Trump's sweeping legislative package is, as expected, divisive. Republicans are pitching it as &#8220;One, Big Beautiful Bill.&#8221; Democrats are <a href="https://www.youtube.com/watch?v=D2cwPUb21IE">calling it</a> &#8220;one big beautiful betrayal.&#8221; Here's a look at some of the bill&#8217;s <a href="https://www.benzinga.com/personal-finance/25/05/45485150/the-one-big-beautiful-bill-would-create-maga-savings-accounts-with-a-1000-gift-from-the-government-at-birth">key elements</a>.&nbsp;
The Winners: The bill seeks to extend The Tax Cuts and Jobs Act (TCJA) of 2017. That means the expiring provisions that benefit high-income and wealthy earners would be permanent.
It also seeks to eliminate federal taxes on tips and overtime pay, fulfilling some of Trump&#8217;s campaign promises.&nbsp;
The tax breaks would reduce revenue by $4.9 trillion over the decade, but increase spending on military, defense and border security. 
So, if legislators sign the bill into law, major U.S. defense contractors like RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) and Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) could benefit from increased defense spending.&nbsp;
Other companies exposed to the defense sector including Palantir Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) and Booz Allen Hamilton Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) could also benefit from increased military and defense spending.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/05/45499101/big-short-legend-michael-burry-bets-big-on-lipstick-index-is-he-bracing-for-a-recession?utm_source=article">&#8216;Big Short&#8217; Legend Michael Burry Bets Big On Lipstick Index: Is He Bracing For A Recession?</a>
The Losers: The cost of the tax bill will be partially balanced with new taxes on private university endowments and significant cuts to programs like Medicaid.
Stocks of major Medicaid managed care organizations could be vulnerable to enrollment volatility and premium pricing challenges if the changes are approved. Investors would be wise to monitor UnitedHealth Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) and Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) as the bill moves through Congress. 
Low-income Americans who rely on food assistance should also take note. House Republicans are proposing major changes to the Supplemental Nutrition Assistance Program, or SNAP. The program aids over 42 million Americans. The bill would shift 5% of benefit costs and 75% of administrative costs to states, up from the current 50% share for administration only. It also seeks to expand work requirements to recipients up to age 64.
Democrats have criticized the move as harmful to families, while Republicans say it promotes work and cuts waste. The House Agriculture Committee has already <a href="https://www.politico.com/live-updates/2025/05/14/congress/house-agriculture-committee-approves-300-billion-in-nutrition-spending-cuts-00350900">approved</a> $300 million in SNAP cuts to help fund tax breaks.
If the<a href="https://www.benzinga.com/general/health-care/25/05/45431505/gop-tax-bill-breaks-trumps-social-security-tax-pledge-still-hits-25-million-seniors-while-elon-musks-stock-wealth-skirts-fica"> legislative package</a> is passed, it would also be the end of many clean energy initiatives and key tax credits and would impose new fees on electric vehicles. These changes could slow the growth of the clean energy sector and make electric vehicles and renewables less competitive compared to traditional energy sources.&nbsp;
Clean energy stocks including Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>), First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) and Sunrun, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) were all sharply lower on Monday as investors digested the potential effects on the industry.&nbsp;
The 1,116-page bill also wouldn&#8217;t quell fears about America&#8217;s public debt, which currently stands at $36 trillion. According to the nonpartisan watchdog group, the Committee for a Responsible Federal Budget, the bill <a href="https://www.crfb.org/blogs/adding-house-reconciliation-bill">adds</a> approximately $3.3 trillion to the national debt over the next ten years.
What's Next: After advancing out of the House Budget Committee in a rare Sunday meeting by a narrow 17-16 vote, Trump&#8217;s &#8220;One Big, Beautiful Bill&#8221; faces several<a href="https://www.benzinga.com/25/05/45481745/donald-trump-backed-gop-bill-seeks-to-ban-states-from-regulating-ai-for-10-years-critics-warn-its-federal-overreach-that-could-backfire"> key steps</a> before it can become law.
The next stop is the House Rules Committee, which will meet midweek to set the terms for floor debate, consider possible amendments, and make any necessary last-minute adjustments to the bill before it heads to a full vote on the House floor. 
If the bill passes the House, it will move to the Senate where it may face additional challenges, as Republican senators are also seeking changes that could complicate final passage.
Further changes to the bill are possible as leaders work to secure enough support from both conservative and moderate factions.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/health-care/25/05/45384935/trump-again-promises-lower-drug-prices-by-cutting-out-middlemen-like-unitedhealth-cvs-will-it-work-this-time?utm_source=articleShare">Trump Again Promises Lower Drug Prices By &#8216;Cutting Out Middlemen&#8217; Like UnitedHealth, CVS: Will It Work This Time?</a></li>
</ul>
Photo: Shutterstock&nbsp;

Trump's 'Big Beautiful Bill' Advances: Here's Who Wins And Loses

Centene's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) short percent of float has fallen 19.26% since its last report. The company recently reported that it has 8.57 million shares sold short, which is 1.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.57 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Centene Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747684836_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Centene has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Centene's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Centene's peer group average for short interest as a percentage of float is 4.72%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Ideas

How Do Investors Really Feel About Centene?

WIIM

ALHC

iShares Trust Dow Jones US Healthcare Sector Index Fund

Shares of health insurance stocks are trading lower after UnitedHealth suspended its 2025 outlook as medical expenditures were expected to be larger than anticipated.

Reported Friday, Arizona Complete Health Secures Six-Year Contract To Lead Arizona Long Term Care Medicaid Services

Jefferies analyst David Windley maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Hold and lowers the price target from $64 to $61.

Price Target

Analyst Ratings

Jefferies Maintains Hold on Centene, Lowers Price Target to $61

Guggenheim analyst Jason Cassorla reiterates Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Neutral to Neutral.

Reiteration

Guggenheim Reiterates Neutral on Centeneto Neutral

4 analysts have shared their evaluations of Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $72.25, a high estimate of $84.00, and a low estimate of $64.00. A decline of 1.37% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1745848869_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Centene. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $84.00&#x7C;$93.00 &#x7C; 
&#x7C;Michael Ha &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $69.00&#x7C;$71.00 &#x7C; 
&#x7C;David Windley &#x7C;Jefferies &#x7C;Raises &#x7C;Hold &#x7C; $64.00&#x7C;$53.00 &#x7C; 
&#x7C;Stephen Baxter &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $72.00&#x7C;$76.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Centene. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Centene compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Centene's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Centene's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CNC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Centene analyst ratings.</a>
<h2>Get to Know Centene Better</h2>
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
<h3>Centene's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Centene's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 3.41%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 0.69%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Centene's ROE excels beyond industry benchmarks, reaching 1.05%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Centene's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.34%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.74, Centene adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 4 Analyst Projections For Centene

Barclays analyst Andrew Mok maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight and lowers the price target from $93 to $84.

Barclays Maintains Overweight on Centene, Lowers Price Target to $84

Wall Street's three-day rally came to a pause on Friday, with major indices hovering near the flatline by midday in New York as caution returned amid mixed signals on <a href="https://www.benzinga.com/news/global/25/04/45004954/china-reportedly-begins-exempting-key-us-imports-from-tariffs-including-pharma-and-aerospace-parts">U.S.-China trade relations.</a>
President Donald Trump claimed to have held a phone call with President Xi Jinping, yet Chinese officials denied that any talks had taken place.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) extended its rally into a fourth consecutive session, notching its best weekly performance of the year with a 16% gain. On Thursday afternoon, Transportation Secretary Sean Duffy introduced a new regulatory framework for self-driving vehicles, saying it aimed to reduce bureaucratic hurdles and advance toward a unified national standard.
T-Mobile US Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NYSE">TMUS</a>) was the biggest laggard of the day, falling 11%, on track for its worst single-day loss since March 2020. This came despite better-than-expected earnings, as its core wireless business posted slower growth than analysts had projected.
Among sectors, consumer discretionary led gains, buoyed by Tesla's 8% gain, while materials underperformed.
In fixed income, Treasury yields declined for a fourth straight session, underscoring how critical Trump's early-week reassurance — that he would not dismiss Fed Chair Jerome Powell — was for bond market sentiment.
The yield on the 10-year Treasury note dropped 4 basis points to 4.27%, on course for its lowest close since April 8.
In commodities, gold slid 2%, oil held steady at $62 per barrel, and natural gas rose 1% to $3 per million British thermal units, snapping a 10-session losing streak.
In crypto markets, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 1.2% to $95,000.
<h2 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,250.90</td>
<td>+0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,488.71</td>
<td>+0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,908.60</td>
<td>-0.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,942.82</td>
<td colspan="2">-0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) flattened at $546.92.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.5% to $399.23.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 0.2% to $468.61.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.7% to $192.79.</li>
<li>The&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 1.1%; the&nbsp;Materials Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) lagged, down 1.1%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
Stocks reacting to earnings report included:
<ul>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>): up 1.7%</li>
<li>T-Mobile US Inc.: down 10.9%</li>
<li>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>): up 2.4%</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>): down 7.2%</li>
<li>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): down 3.2%</li>
<li>Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>): down 11.0%</li>
<li>Republic Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>): down 0.2%</li>
<li>Digital Realty Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>): up 3.0%</li>
<li>HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>): down 5.2%</li>
<li>Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>): up 10.3%</li>
<li>The Hartford Financial Services Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>): down 1.1%</li>
<li>Weyerhaeuser Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>): down 2.1%</li>
<li>Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>): up 1.1%</li>
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>): down 7.7%</li>
<li>LyondellBasell Industries N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>): up 0.0%</li>
<li>VeriSign Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>): up 9.1%</li>
<li>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>): down 2.0%</li>
<li>Carrier Global Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>): down 0.5%</li>
<li>Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>): down 0.7%</li>
<li>Erie Indemnity Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>): down 11.8%</li>
<li>Principal Financial Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>): down 1.4%</li>
<li>Eastman Chemical Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>): down 6.0%</li>
<li>Healthpeak Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>): down 4.7%</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45009066/goldman-sachs-upgrades-charles-schwab-to-buy-one-of-the-best-earnings-growth-outlooks-analyst-says">Goldman Sachs Upgrades Charles Schwab To Buy: &#8216;One Of The Best Earnings Growth Outlooks,&#8217; Analyst Says</a></li>
</ul>
Photo: Shutterstock

Equities

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

$BTC

ABBV

CARR

CHTR

SPDR Dow Jones Industrial Average ETF Trust

GILD

GOOGL

INTC

TMUS

TSLA

VRSN

Select Sector SPDR-Consumer Discretionary

Wall Street Rally Pauses, Tesla Heads For Strongest Week In 6 Months: What's Driving Markets Friday?

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 20 years by 2.97% on an annualized basis producing an average annual return of 11.01%. Currently, Centene has a market capitalization of $28.44 billion. 
Buying $100 In CNC: If an investor had bought $100 of CNC stock 20 years ago, it would be worth $798.95 today based on a price of $57.33 for CNC at the time of writing.
<h3>Centene's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745598624_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Centene Stock In The Last 20 Years

Centene shares are trading lower after the company issued FY25 EPS guidance below estimates.

Centene Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) reported on Friday that its first-quarter&nbsp;2025 sales were&nbsp;$46.62 billion, up 15% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of&nbsp;$43.36 billion</a>.
The insurance firm reported adjusted EPS of $2.90, up 28%, beating the consensus of $2.54.
For the first quarter of 2025, premium and service revenues increased 17% to&nbsp;$42.5 billion&nbsp;from&nbsp;$36.3 billion&nbsp;a year ago, primarily driven by premium and membership growth in the PDP business, strong product positioning, and overall market growth <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n45003190/centene-corporation-reports-first-quarter-2025-results" rel="noreferrer noopener">in the Marketplace business</a>.
The health benefits ratio (HBR) of 87.5% for the first quarter of 2025 represents an increase from 87.1% a year ago due to higher Medicaid HBR due to influenza-and-like illnesses.
<ul>
<li>The company adds that the Medicaid HBR in the first quarter of 2024 was not meaningfully impacted by the redetermination-related acuity pressure, which escalated in the second quarter of 2024.</li>
<li>The increase in HBR was partially offset by a decrease in Medicare due to program changes in the Part D business due to the Inflation Reduction Act compared to the first quarter of 2024 and the resulting change in the quarterly progression of the Medicare segment HBR.</li>
<li>Total membership reached 27.94 million, down from 28.42 million a year ago.</li>
<li>Medicaid membership fell from 13.29 million to 12.96 million.</li>
<li>The company saw membership increases of 29% in Marketplace to 5.63 million and 22% in Medicare Prescription Drug Plan (PDP) to 7.87 million compared to the first quarter of 2024.</li>
</ul>
Centene CEO Sarah London noted that the company&#8217;s full-year 2025 adjusted diluted earnings per share outlook was greater than $7.25.
Guidance: Centene raised its 2025 premium and service revenue guidance window by $6 billion on Friday. The company now expects 2025 premium and service revenue of $164 billion to $166 billion compared to $158 billion-$160 billion expected earlier, including:
<ul>
<li>$5 billion of additional Marketplace premium revenue due to outperformance in enrollment throughout the first quarter.</li>
<li>Outperformance in the Medicare Advantage annual enrollment period resulting in&nbsp;$1.0 billion&nbsp;of additional premium revenue.</li>
</ul>
Centene reaffirms fiscal year 2025 <a href="https://www.benzinga.com/25/02/43470058/insurance-firm-centenes-q4-earnings-enrollment-and-premium-boost-revenue-to-offset-lower-medicaid-enrollment-sticks-to-annual-forecast">adjusted EPS of greater than&nbsp;$7.25</a> compared to consensus of $7.23.
Price Action: Centene stock is down 1.19% at $60.85 during the premarket session at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44999959/how-the-us-china-trade-war-is-unintentionally-boosting-demand-for-intels-older-chips-amid-economic-uncertainty" target="_blank" rel="noreferrer noopener">Intel&#8217;s Older Parts Are In Demand Thanks To US-China Trade War: &#8216;Tariffs Have Everybody Hedging Their Bets,&#8217; Says Executive</a></li>
</ul>

Earnings

Guidance

General

Insurer Centene Reaffirms Annual Profit Guidance, Reports Better Than Expected Q1 Earnings

UPDATE: Centene Expects FY25 Adj. EPS Of More Than $7.25 Vs $7.23 Estimate

UPDATE: Centene Expects GAAP FY2025 EPS Of More Than $6.19 Vs $6.23 Estimate

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) reported quarterly earnings of $2.90 per share which beat the analyst consensus estimate of $2.54 by 14.17 percent. This is a 28.32 percent increase over earnings of $2.26 per share from the same period last year. The company reported quarterly sales of $46.62 billion which beat the analyst consensus estimate of $43.36 billion by 7.52 percent. This is a 15.38 percent increase over sales of $40.41 billion the same period last year.

Earnings Beats

Centene Q1 Adj. EPS $2.90 Beats $2.54 Estimate, Sales $46.62B Beat $43.36B Estimate

<h3>Companies Reporting Before The Bell</h3>
• Gentex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTX#NASDAQ">GNTX</a>) is projected to report quarterly earnings at $0.42 per share on revenue of $572.09 million. 
• Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) is estimated to report quarterly earnings at $2.76 per share on revenue of $811.53 million. 
• Phinia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHIN#NYSE">PHIN</a>) is estimated to report quarterly earnings at $1.00 per share on revenue of $814.11 million. 
• Virtus Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTS#NYSE">VRTS</a>) is estimated to report quarterly earnings at $5.41 per share on revenue of $201.41 million. 
• Stellar Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEL#NYSE">STEL</a>) is expected to report quarterly earnings at $0.44 per share on revenue of $105.66 million. 
• AutoNation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) is estimated to report quarterly earnings at $4.38 per share on revenue of $6.64 billion. 
• Sensient Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXT#NYSE">SXT</a>) is estimated to report quarterly earnings at $0.82 per share on revenue of $387.70 million. 
• Carter's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $623.41 million. 
• Flagstar Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLG#NYSE">FLG</a>) is expected to report quarterly loss at $0.28 per share on revenue of $509.58 million. 
• Portland Gen Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) is estimated to report quarterly earnings at $0.99 per share on revenue of $970.49 million. 
• AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is likely to report quarterly earnings at $2.38 per share on revenue of $12.92 billion. 
• HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) is expected to report quarterly earnings at $5.76 per share on revenue of $18.26 billion. 
• Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) is projected to report quarterly earnings at $8.69 per share on revenue of $13.68 billion. 
• Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) is projected to report quarterly earnings at $0.74 per share on revenue of $8.60 billion. 
• Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) is expected to report quarterly loss at $0.72 per share on revenue of $31.33 billion. 
• Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) is projected to report quarterly earnings at $0.86 per share on revenue of $4.86 billion. 
• LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) is expected to report quarterly earnings at $0.43 per share on revenue of $7.46 billion. 
• Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) is expected to report quarterly earnings at $6.02 per share on revenue of $4.86 billion. 
• Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) is expected to report quarterly earnings at $2.54 per share on revenue of $43.36 billion. 
• Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) is expected to report earnings for its fourth quarter. 
• Lakeland Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKFN#NASDAQ">LKFN</a>) is expected to report quarterly earnings at $0.89 per share on revenue of $63.71 million. 
• GrafTech International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NYSE">EAF</a>) is likely to report quarterly loss at $0.13 per share on revenue of $122.33 million. 
• Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) is projected to report quarterly earnings at $0.23 per share on revenue of $1.61 billion. 
• Oxford Square Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXSQ#NASDAQ">OXSQ</a>) is expected to report quarterly earnings at $0.08 per share on revenue of $9.90 million. 
• Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) is expected to report quarterly earnings at $0.36 per share on revenue of $654.15 million. 
• Preferred Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFBC#NASDAQ">PFBC</a>) is estimated to report quarterly earnings at $2.33 per share on revenue of $70.51 million. 
• Rithm Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RITM#NYSE">RITM</a>) is likely to report quarterly earnings at $0.47 per share on revenue of $1.27 billion. 
• Trinet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNET#NYSE">TNET</a>) is projected to report quarterly earnings at $1.61 per share on revenue of $319.36 million. 
<h3>Companies Reporting After The Bell</h3>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADXN

AVTR

GNTX

LKFN

OXSQ

PFBC

PHIN

RITM

SAIA

STEL

TNET

VRTS

Earnings Scheduled For April 25, 2025

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) is gearing up to announce its quarterly earnings on Friday, 2025-04-25. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Centene will report an earnings per share (EPS) of $2.45.
Centene bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company beat EPS by $0.31, leading to a 0.91% drop in the share price the following trading session.
Here's a look at Centene's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.49</td>
<td>1.38</td>
<td>2.07</td>
<td>2.08</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.80</td>
<td>1.62</td>
<td>2.42</td>
<td>2.26</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>4.0%</td>
<td>8.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745503269_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Centene were trading at $62.12 as of April 23. Over the last 52-week period, shares are down 18.86%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Insights Shared by Analysts on Centene</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Centene.
Analysts have provided Centene with 3 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $68.33, suggesting a potential 10.0% upside.
<h3>Analyzing Ratings Among Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Molina Healthcare, HealthEquity and Alignment Healthcare, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Molina Healthcare, with an average 1-year price target of $368.6, suggesting a potential 493.37% upside.</li>
<li>Analysts currently favor an Outperform trajectory for HealthEquity, with an average 1-year price target of $111.11, suggesting a potential 78.86% upside.</li>
<li>Analysts currently favor an Buy trajectory for Alignment Healthcare, with an average 1-year price target of $18.19, suggesting a potential 70.72% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary presents essential metrics for Molina Healthcare, HealthEquity and Alignment Healthcare, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centene</td>
<td>Neutral</td>
<td>3.41%</td>
<td>$3.72B</td>
<td>1.05%</td>
</tr>
<tr>
<td>Molina Healthcare</td>
<td>Neutral</td>
<td>16.04%</td>
<td>$1.11B</td>
<td>5.42%</td>
</tr>
<tr>
<td>HealthEquity</td>
<td>Outperform</td>
<td>18.84%</td>
<td>$189.04M</td>
<td>1.24%</td>
</tr>
<tr>
<td>Alignment Healthcare</td>
<td>Buy</td>
<td>50.68%</td>
<td>$86.34M</td>
<td>-29.00%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Centene ranks in the middle among its peers for revenue growth, with one peer showing the highest growth. Centene's gross profit is the highest among its peers. However, its return on equity is lower compared to some peers. Overall, Centene's performance is solid but there is room for improvement in return on equity.
<h3>Unveiling the Story Behind Centene</h3>
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
<h3>Understanding the Numbers: Centene's Finances</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Centene displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 3.41%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Centene's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 0.69%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.05%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Centene's ROA excels beyond industry benchmarks, reaching 0.34%. This signifies efficient management of assets and strong financial health.
Debt Management: Centene's debt-to-equity ratio is below the industry average. With a ratio of 0.74, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/CNC/earnings">To track all earnings releases for Centene visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Centene's Earnings: A Preview

Shares of health insurance stocks are trading lower in sympathy with UnitedHealth, which reported worse-than-expected Q1 results and cut its FY25 adjusted EPS guidance below estimates on Thursday.

Shares of health insurance stocks are trading lower in sympathy with UnitedHealth, which reported worse-than-expected Q1 results and cut its FY25 adjusted EPS guidance below estimates.

Comments

Centene

Centene (CNC) 옵션

Loading...

뉴스

파트너 / 기고자

벤징가 글로벌